November 01, 2018
Rose
GlaxoSmithKline reports that demand for Shingrix -- the drugmaker's new shingles vaccine that was granted favored status by the Centers for Disease Control and Prevention last year -- is driving healthy profits.
from Kaiser Health News https://ift.tt/2RvILWF
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment